News Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:55 26/04/2024 BST			5-day change	1st Jan Change
28.15 ^DKK	+0.72%		+0.90%	-18.50%

04-09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
04-09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	04-09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	CI
Lundbeck : Articles of Association	04-02	PU
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	03-27	MT
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	03-27	AQ
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	03-27	CI
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	03-20	AQ
H. Lundbeck A/S Announces Management Appointments	03-20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	03-20	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	03-20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	03-15	MT
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage	03-15	AQ
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	03-15	CI
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders	03-05	AQ
Notice of Annual General Meeting	02-23	AQ
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	02-23	CI
Lundbeck announces changes to Executive Management	02-23	AQ
H. Lundbeck A/S Announces Changes to Executive Management	02-23	CI
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss	02-13	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Summary

Filters